Department of Thoracic and Cardiovascular Surgery, Loyola University, Maywood, IL 60153, USA.
Transplantation. 2009 Dec 27;88(12):1341-8. doi: 10.1097/TP.0b013e3181bcde7b.
Rat lung allograft rejection is mediated by collagen type V (col(V)) specific T-helper-cell 17 (Th17) cells. Adoptive transfer of these cells is sufficient to induce rejection pathology in isografts, whereas tolerance to col(V) suppresses allograft rejection. Therefore, we tested whether regulatory T cells from tolerant rats could suppress the Th17-mediated rejection in the syngeneic model of lung transplantation.
Rats were subjected to syngeneic left lung transplantation, and acute rejection was induced by adoptive transfer of lymph node cells from col(V)-immunized rats. Tolerance was induced by intravenous injection of col(V), and spleen lymphocytes were used for adoptive transfer. CD4+ T cells were depleted using magnetic beads. Lung isografts were analyzed using micro-positron emission tomography imaging and histochemistry. The transvivo delayed type hypersensitivity assay was used to analyze the Th17 response.
Adoptive cotransfer of col(V)-specific effector cells with cells from col(V)-tolerized rats suppressed severe vasculitis and bronchiolitis with parenchymal inflammation, and the expression of interleukin (IL)-17 transcripts in mediastinal lymph nodes induced by effector cells alone. Analysis by transvivo delayed type hypersensitivity showed that the reactivity to col(V) was dependent on the presence of tumor necrosis factor-alpha and IL-17 but not interferon-gamma. Depletion of CD4+ T cells from the suppressor cell population abrogated the col(V)-specific protection.
Th17-mediated acute rejection after lung transplantation is ameliorated by CD4+ col(V)-specific regulatory T cells. The mechanism for this Th17 suppression is consistent with tolerance induction to col(V). The goal of transplantation treatment, therefore, should target Th17 development and not suppression of T-cell activation by suppressing IL-2.
大鼠肺同种异体移植排斥反应是由胶原 V(col(V)) 特异性 T 辅助细胞 17(Th17)细胞介导的。这些细胞的过继转移足以在同种异体移植物中诱导排斥病理,而 col(V)的耐受性抑制同种异体移植排斥。因此,我们测试了来自耐受大鼠的调节性 T 细胞是否可以抑制 Th17 介导的肺移植的同种异体模型中的排斥反应。
大鼠接受同基因左肺移植,通过过继转移 col(V)免疫大鼠的淋巴结细胞诱导急性排斥反应。通过静脉注射 col(V)诱导耐受性,并用脾淋巴细胞进行过继转移。使用磁珠耗尽 CD4+T 细胞。通过微正电子发射断层扫描成像和组织化学分析肺同种异体移植物。采用转染迟发型超敏反应试验分析 Th17 反应。
与 col(V)特异性效应细胞一起过继转移 col(V)耐受大鼠的细胞抑制了严重的血管炎和细支气管炎伴实质炎症,以及效应细胞单独诱导的纵隔淋巴结中白细胞介素(IL)-17 转录物的表达。转染迟发型超敏反应分析表明,对 col(V)的反应依赖于肿瘤坏死因子-α和 IL-17 的存在,而不依赖于干扰素-γ。从抑制细胞群中耗尽 CD4+T 细胞会破坏 col(V)特异性保护。
肺移植后 Th17 介导的急性排斥反应通过 CD4+col(V)特异性调节性 T 细胞得到改善。这种 Th17 抑制的机制与 col(V)的诱导耐受一致。因此,移植治疗的目标应该是针对 Th17 的发展,而不是通过抑制 IL-2 抑制 T 细胞的激活。